Stay updated with breaking news from Virtual Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UK neuroscience company NRG Therapeutics Ltd has received an award to fund preclinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other chronic neurodegenerative disorders.
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.
/PRNewswire/ -- NRG Therapeutics Ltd ("NRG" or "company"), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that...
In recognition of World Parkinson's Day, we speak to Dr. Arthur Roach, Director of Research at Parkinson’s UK, about the current Parkinson's landscape.
HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics